Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Phase determination using chromosomal microarray and fluorescence in situ hybridization in a patient with early onset Parkinson disease and two deletions in PRKN.

Williams ES, Barrett MJ, Dhamija R, Toran L, Chambers C, Mahadevan MS, Golden WL.

Mol Genet Genomic Med. 2018 May;6(3):457-462. doi: 10.1002/mgg3.386. Epub 2018 Mar 25.

2.

The influence of endogenous attention on contrast perception, contrast discrimination, and saccadic reaction time.

Mahadevan MS, Bedell HE, Stevenson SB.

Vision Res. 2018 Feb;143:89-102. doi: 10.1016/j.visres.2017.11.005. Epub 2017 Dec 8.

PMID:
29180106
3.

Disease Phenotypes in a Mouse Model of RNA Toxicity Are Independent of Protein Kinase Cα and Protein Kinase Cβ.

Kim YK, Yadava RS, Mandal M, Mahadevan K, Yu Q, Leitges M, Mahadevan MS.

PLoS One. 2016 Sep 22;11(9):e0163325. doi: 10.1371/journal.pone.0163325. eCollection 2016.

4.

TWEAK Regulates Muscle Functions in a Mouse Model of RNA Toxicity.

Yadava RS, Foff EP, Yu Q, Gladman JT, Zheng TS, Mahadevan MS.

PLoS One. 2016 Feb 22;11(2):e0150192. doi: 10.1371/journal.pone.0150192. eCollection 2016. Erratum in: PLoS One. 2018 Feb 8;13(2):e0192816.

5.

Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by T-cell receptor gene rearrangement analysis: a case series of four patients and review of the literature.

Stowman AM, Hsia LL, Kanner WA, Mahadevan MS, Bullock GC, Patterson JW.

Int J Dermatol. 2016 Feb;55(2):e62-71. doi: 10.1111/ijd.12847. Epub 2015 Aug 12. Review.

PMID:
26266670
6.

TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy.

Yadava RS, Foff EP, Yu Q, Gladman JT, Kim YK, Bhatt KS, Thornton CA, Zheng TS, Mahadevan MS.

Hum Mol Genet. 2015 Apr 1;24(7):2035-48. doi: 10.1093/hmg/ddu617. Epub 2014 Dec 11.

7.

NKX2-5, a modifier of skeletal muscle pathology due to RNA toxicity.

Gladman JT, Yadava RS, Mandal M, Yu Q, Kim YK, Mahadevan MS.

Hum Mol Genet. 2015 Jan 1;24(1):251-64. doi: 10.1093/hmg/ddu443. Epub 2014 Aug 28.

8.

Development of an AP-FRET based analysis for characterizing RNA-protein interactions in myotonic dystrophy (DM1).

Rehman S, Gladman JT, Periasamy A, Sun Y, Mahadevan MS.

PLoS One. 2014 Apr 29;9(4):e95957. doi: 10.1371/journal.pone.0095957. eCollection 2014.

9.

Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1).

Gladman JT, Mandal M, Srinivasan V, Mahadevan MS.

PLoS One. 2013 Sep 5;8(9):e72907. doi: 10.1371/journal.pone.0072907. eCollection 2013.

10.

Evaluating the effects of CELF1 deficiency in a mouse model of RNA toxicity.

Kim YK, Mandal M, Yadava RS, Paillard L, Mahadevan MS.

Hum Mol Genet. 2014 Jan 15;23(2):293-302. doi: 10.1093/hmg/ddt419. Epub 2013 Sep 2.

11.

Myotonic dystrophy: is a narrow focus obscuring the rest of the field?

Mahadevan MS.

Curr Opin Neurol. 2012 Oct;25(5):609-13. doi: 10.1097/WCO.0b013e328357b0d9. Review.

12.

The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicing.

Ravel-Chapuis A, Bélanger G, Yadava RS, Mahadevan MS, DesGroseillers L, Côté J, Jasmin BJ.

J Cell Biol. 2012 Mar 19;196(6):699-712. doi: 10.1083/jcb.201108113.

13.

Therapeutics development in myotonic dystrophy type 1.

Foff EP, Mahadevan MS.

Muscle Nerve. 2011 Aug;44(2):160-9. doi: 10.1002/mus.22090. Epub 2011 May 23. Review.

14.

Myotonic muscular dystrophy, RNA toxicity, and the brain: trouble making the connection?

Mahadevan MS.

Cell Stem Cell. 2011 Apr 8;8(4):349-50. doi: 10.1016/j.stem.2011.03.007.

15.

Genetics. Exposing a DUX tale.

Mahadevan MS.

Science. 2010 Sep 24;329(5999):1607-8. doi: 10.1126/science.1195984. No abstract available.

PMID:
20929834
16.

The effect of myotonic dystrophy transcript levels and location on muscle differentiation.

Mastroyiannopoulos NP, Chrysanthou E, Kyriakides TC, Uney JB, Mahadevan MS, Phylactou LA.

Biochem Biophys Res Commun. 2008 Dec 12;377(2):526-531. doi: 10.1016/j.bbrc.2008.10.031. Epub 2008 Oct 16.

PMID:
18930030
17.

Detection of immunoglobulin heavy chain gene rearrangements in classic hodgkin lymphoma using commercially available BIOMED-2 primers.

Chute DJ, Cousar JB, Mahadevan MS, Siegrist KA, Silverman LM, Stoler MH.

Diagn Mol Pathol. 2008 Jun;17(2):65-72. doi: 10.1097/PDM.0b013e318150d695.

PMID:
18382369
18.

Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats.

Dhaenens CM, Schraen-Maschke S, Tran H, Vingtdeux V, Ghanem D, Leroy O, Delplanque J, Vanbrussel E, Delacourte A, Vermersch P, Maurage CA, Gruffat H, Sergeant A, Mahadevan MS, Ishiura S, Buée L, Cooper TA, Caillet-Boudin ML, Charlet-Berguerand N, Sablonnière B, Sergeant N.

Exp Neurol. 2008 Apr;210(2):467-78. doi: 10.1016/j.expneurol.2007.11.020. Epub 2007 Dec 4.

PMID:
18177861
19.

RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression.

Yadava RS, Frenzel-McCardell CD, Yu Q, Srinivasan V, Tucker AL, Puymirat J, Thornton CA, Prall OW, Harvey RP, Mahadevan MS.

Nat Genet. 2008 Jan;40(1):61-8. Epub 2007 Dec 16.

20.

Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.

Mahadevan MS, Yadava RS, Yu Q, Balijepalli S, Frenzel-McCardell CD, Bourne TD, Phillips LH.

Nat Genet. 2006 Sep;38(9):1066-70. Epub 2006 Jul 30.

Supplemental Content

Loading ...
Support Center